<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">QUININE SULFATE</span><br/>(kwye'nine)<br/><span class="topboxtradename">Novoquinine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Quinamm, </span><span class="topboxtradename">Quiphile<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b>Chloroquine<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 260 mg, 325 mg capsules; 260 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Chief alkaloid from bark of cinchona tree. Exact mechanism of antimalarial action uncertain. Inhibits protein synthesis and
         depresses many enzyme systems in malaria parasite. Has schizonticidal action and is gametocidal with <i>Plasmodium vivax</i> and <i>Plasmodium malariae</i> but not <i>Plasmodium falciparum.</i> Resembles salicylates in analgesic and antipyretic properties and exerts curare-like skeletal muscle relaxant effect. Also
         has oxytocic action and hypoprothrombinemic effect. Qualitatively similar to quinidine in cardiovascular effects. Generally
         replaced by less toxic and more effective agents in treatment of malaria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Plasmodium vivax</i> and <i>Plasmodium malariae</i> but not <i>Plasmodium falciparum</i>. Generally replaced by less toxic and more effective agents in treatment of malaria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Chloroquine-resistant falciparum malaria and in combination with other antimalarials for radical cure of relapsing vivax malaria;
         also relief of nocturnal recumbency leg cramps.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Tinnitus, optic neuritis; myasthenia gravis; G6PD deficiency; pregnancy (category X), avoid use during lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac arrhythmias. Same precautions as for quinidine sulfate when used in patients with cardiovascular conditions.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 650 mg q8h for 3 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 25 mg/kg/d in three divided doses q8h for 3 d<br/><br/><span class="indicationtitle">Malaria Chemoprophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 325 mg b.i.d. for 6 wk<br/><br/><span class="indicationtitle">Nocturnal Leg Cramps</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 260300 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or after meals or a snack to minimize gastric irritation. Quinine has potent local irritant effect on gastric mucosa.
            Do not crush capsule; drug is not only irritating but also extremely bitter.
         </li>
<li>Store in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Cinchonism (tinnitus, decreased auditory acuity, dizziness, vertigo, headache, visual impairment, <span class="speceff-common">nausea, vomiting, diarrhea</span>, fever); hypersensitivity (cutaneous flushing, visual impairment, pruritus, skin rash, fever, gastric distress, dyspnea,
      tinnitus); <span class="speceff-life">hypothermia, coma</span>. <span class="typehead">CNS:</span> Confusion, excitement, apprehension, syncope, delirium, convulsions, blackwater fever (extensive intravascular hemolysis with
      renal failure), <span class="speceff-life">death</span>. <span class="typehead">CV:</span> Angina, hypotension, tachycardia, <span class="speceff-life">cardiovascular collapse</span>. <span class="typehead">Hematologic:</span> Leukopenia, thrombocytopenia, <span class="speceff-life">agranulocytosis</span>, hypoprothrombinemia, hemolytic anemia. <span class="typehead">Respiratory:</span> Decrease respiration. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Quinine may interfere with determinations of <span class="alt">urinary catecholamines</span> (<span class="alt">Sobel</span> and <span class="alt">Henry modification procedure</span>) and <span class="alt">urinary steroids</span>
<span class="alt">(17-hydroxycorticosteroids)</span> (modification of <span class="alt">Reddy,</span>
<span class="alt">Jenkins,</span>
<span class="alt">Thorn</span> method).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>digoxin</b> levels; <span class="classification">anticholinergic agents</span> add to vagolytic effects; <span class="classification">cholinergic agents</span> may antagonize cardiac effects; <span class="classification">anticonvulsants</span>, <span class="classification">barbiturates</span>, <b>rifampin</b> increase the metabolism of quinine, thus decreasing its efficacy; <span class="classification">carbonic anhydrase inhibitors</span>, <b>sodium bicarbonate,</b>
<span class="classification">chronic antacids</span> decrease renal elimination of quinine, thus increasing its toxicity; <b>warfarin</b> may increase hypoprothrombinemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 68 h. <span class="typehead">Distribution:</span> Widely distributed to most body tissues except the brain; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> &gt;95% excreted in urine, Half-Life: 821 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be alert for S&amp;S of rising plasma concentration of quinine marked by tinnitus and hearing impairment, which usually do not
            occur until concentration is 10 mcg/mL or more.
         </li>
<li>Follow the same precautions with quinine as are used with quinidine in patients with atrial fibrillation; quinine may produce
            cardiotoxicity in these patients.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn possible adverse reactions and report onset of any unusual symptom promptly to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>